Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
暂无分享,去创建一个
M. Stockler | W. Parulekar | M. Frydenberg | L. Horvath | J. McCaffrey | I. Davis | F. Vera-Badillo | S. Chowdhury | C. Sweeney | K. Chi | W. Hague | R. McDermott | M. Reaume | S. Sandhu | A. Joshua | S. North | T. Tan | F. Parnis | A. Martin | S. Begbie | X. Coskinas | Scott G. Williams | D. Pook | R. Zielinski | G. Marx | N. Lawrence | A. Zhang | S. Yip | A. Thomson | M. McJannett | E. Tu | M. Mcjannett | A. Tan | S. Williams
[1] Joshua M. Stuart,et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance , 2020, Proceedings of the National Academy of Sciences.
[2] T. Derlin,et al. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy , 2020, BMC Cancer.
[3] Mary E. Hall,et al. Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape , 2020, OncoTargets and therapy.
[4] Jianjun Yu,et al. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer , 2020, EBioMedicine.
[5] M. Freeman,et al. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential , 2020, BMC Cancer.
[6] M. Parmar,et al. Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. DiPaola,et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. , 2018, European urology.
[8] M. Parmar,et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Y. Park,et al. Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.
[11] M. Parmar,et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.
[12] S. Culine,et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.
[13] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[14] M. Parmar,et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.
[15] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[16] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[17] A. Ravaud,et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.
[18] Samir S Taneja,et al. Re: Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2013, The Journal of urology.
[19] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[20] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[21] I. Tannock,et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[24] Edward L Spitznagel,et al. Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.
[25] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[26] M D Hughes,et al. Practical problems in interim analyses, with particular regard to estimation. , 1989, Controlled clinical trials.